RxDoctor Payments Data

Sandra Flores

Family · Edinburg, TXNPI 1649602145

Payments from drug & device makers

$7,321in general payments, 2019–2025

Across 267 payments — averaging $27.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$970
  • GSK$768
  • Lilly USA, LLC$524
  • Bayer$320
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$7,305100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,321 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$66,089
MounjaroTirzepatide19$31,807
JardianceEmpagliflozin26$24,926
FarxigaDapagliflozin Propanediol15$16,446
KerendiaFinerenone17$13,934
LinzessLinaclotide11$8,118
EliquisApixaban13$7,776
Omega-3 Acid Ethyl Esters15$1,912
Atorvastatin Calcium70$699
Alendronate Sodium47$694
Diclofenac Sodium19$570
Rosuvastatin Calcium37$534
Omeprazole17$392
FenofibrateFenofibrate Nanocrystallized11$387
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide14$369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,278$66,08956 claims
Lilly USA, LLCMounjaro$524$31,80719 claims
Boehringer IngelheimJardiance$203$24,92626 claims
AstraZenecaFarxiga$1,249$16,44615 claims
BayerKerendia$320$13,93417 claims
AbbVieLinzess$970$8,11811 claims
PfizerEliquis$48$7,77613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Edinburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →